"A large Canadian specialty pharmaceutical company was a market darling wherein its debt funded acquisition led growth was cheered and rewarded by the market. Our QoE analysis in April 2015 focused on:
Aggressive B/S: Alarming Debt to Equity ratio, poor AZS 1, poor debt servicing ratios etc...